The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Thirty-five men with newly diagnosed, metastatic prostate cancer are scanned with 18F-PSMA
1007 PET/CT at baseline, 3 weeks after the initiation of GnRH-antagonist, at one year and at
the time of castration resistant prostate cancer (CRPC). The aim of the study is to classify
metastatic lesions into those with PSMA-flare and those without and determine their potential
to progress during the follow-up until CRPC.